Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
This Month's Exclusive Story Why 2 Small Biotechs May Hold the Key to New Cancer TreatmentsAuthor: Nathan Reiff. Article Posted: 3/12/2026. 
Key Points - Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
- Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
- Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
- Special Report: The Biggest IPO Ever: Claim Your Stake Today
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to grow to $366 billion over the next eight years. Many companies take a niche approach, developing medicines that target specific cancer types with tailored mechanisms. A number of promising treatments have emerged—and with them, the potential for significant sales. Two smaller biotech companies have seen strong share-price momentum thanks to their leading oncology medicines. Beyond therapeutic potential, these drugs could help the firms move past penny-stock or otherwise unstable status and toward longer-term stability. That said, both companies still face substantive risks; like many biotechs, they remain high-risk investments with the potential for outsized rewards for investors willing to accept the uncertainty. Iovance's Powerful Cancer Drug Is Growing, But Production Challenges Are a Hurdle San Francisco is the strangest city in America right now—you can hop into a self-driving car and be chauffeured by a robot, but out the window you see addicts slumped in doorways, open-air drug markets, the mentally ill screaming at the sky, and entire city blocks consumed by homeless encampments. It's ground-zero for the most disruptive technological forces of our age, and Erez lives in the Bay Area plugged into the capital, the connections, and the companies reshaping the world—the advancements in AI, blockchain, computing, and biosciences are unlike anything the world has seen before, and a tsunami of disruption is coming for everything all at once. During our most recent broadcast, we exposed what we're calling the most asymmetric opportunity of our careers: an overlooked financial company hiding a multi-billion-dollar blockchain asset Wall Street hasn't priced in—it's one of those rare situations Warren Buffett would describe as raining gold when all you have to do is step outside if you want to get rich. Watch the broadcast before the window closes now Iovance Biotherapeutics Inc. (NASDAQ: IOVA) bucked broader market weakness in early March, rallying nearly 37% in a week when the S&P 500 slipped roughly 1%. That added to IOVA's year-to-date (YTD) performance, during which shares have more than doubled. Still, with a consensus price target of $8.88, Wall Street implies there may be further upside—about 71% from current levels. The primary catalyst for Iovance is Amtagvi, a T‑cell immunotherapy for certain forms of melanoma. Amtagvi was approved in the United States in 2024 and is gaining momentum—both in sales and in the prospect of additional approvals in the EU, U.K., and elsewhere. When administered with Proleukin, the company's IL‑2 immunotherapy, management expects Amtagvi could achieve more than $1 billion in peak U.S. sales. Amtagvi may also have broader potential outside melanoma: it received FDA Fast Track designation for non‑small cell lung cancer and is being evaluated for other tumor types. Iovance's late‑February Q4 2025 earnings report helped fuel recent gains, with a better‑than‑expected loss per share and $5 million in revenue. For the full year, revenue rose roughly 30% year‑over‑year (YOY). That said, Iovance remains a small‑cap biotech (about $2 billion market cap) and still qualifies as a penny stock, and analysts are cautious: about half of its roughly a dozen coverage ratings are Hold or Sell. A key risk is manufacturing. Because Amtagvi is a personalized, costly, and complex therapy to produce, production constraints and high costs could limit Iovance's ability to generate profit even if demand increases. Massive Sales Growth for ImmunityBio's Bladder Cancer Drug ImmunityBio Inc. (NASDAQ: IBRX) slipped about 20% in March, but its year‑to‑date performance dwarfs Iovance's: IBRX shares are up nearly 300% in 2026 alone. Analysts' consensus price target of $13.60 still implies roughly 70% upside from current levels. ImmunityBio's lead product is Anktiva, a treatment for certain bladder cancers. In February, shares jumped after the EU regulator granted the drug conditional marketing authorization—the latest in a series of approvals worldwide. Anktiva has driven the company's revenue, with $113 million in sales last year—approximately a 700% YOY increase. Like Amtagvi, Anktiva may have additional indications under study, and ImmunityBio is exploring those possibilities. Despite the stock's dramatic run, IBRX remains speculative. The company reported a full‑year net loss of $351 million for 2025 as R&D spending continues to mount. Analysts are somewhat more bullish on ImmunityBio than on Iovance: six of seven covering analysts rate the stock a Buy or equivalent. Both companies illustrate the biotech risk‑reward tradeoff—breakthrough oncology drugs can drive rapid share appreciation and meaningful revenue, but regulatory, manufacturing, and cash‑burn risks can quickly reverse fortunes. Investors should weigh those factors carefully before committing capital. | 
